European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

The pandemic within: tackling brain vulnerability in COVID19 at high resolution: NEUROCOV

Descrizione del progetto

Cura per le complicanze neurologiche della COVID-19

L’impatto delle frequenti complicanze neurologiche e psichiatriche derivanti dall’infezione da SARS-CoV-2 può essere devastante su scala pandemica a causa della mancanza di cure. Il progetto NEUROCOV, finanziato dall’UE, studierà pertanto le complicanze cognitive e neurodegenerative associate alla COVID-19, la cosiddetta NeuroCOVID, utilizzando un approccio interdisciplinare innovativo. L’obiettivo è sviluppare una metodologia per anticipare e gestire le vulnerabilità personalizzate e il loro impatto a livello di popolazione. L’approccio ampio coinvolgerà l’epidemiologia, la ricerca dell’interazione ospite/virus a livello di singola cellula e la modellazione predittiva per identificare biomarcatori e potenziali farmaci da riproporre. Lo spettro fenotipico della NeuroCOVID sarà ottenuto attraverso i principali registri sanitari nazionali e tre coorti cliniche, il che consente di analizzare le complicanze, i fattori di rischio e l’onere socioeconomico.

Obiettivo

The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare. Despite the towering success of vaccine development, lack of preparedness on integrative clinical and molecular phenotyping has emerged with clarity and highlights the need to scale translational efforts for personalized prevention and therapy. Of particular concern are the long-term consequences of SARS-CoV-2 infection with high and rising prevalence of chronic manifestations referred to as Post-COVID. Among these the neurological and psychiatric complications stand out for frequency, lack of treatment and devastating impact of their effects at pandemic scale. Here, we tackle the cognitive and neurodegenerative complications of COVID-19, referred to as NeuroCOVID, as a ticking pandemic within the pandemic that requires an innovation leap across disciplines. We pursue a multi scalar approach that reaches from epidemiology and mechanistic interrogation of host/virus interplay at single cell resolution through predictive modelling all the way to validation of biomarkers and repurposed drugs. The aim is to anticipate and effectively manage personalized trajectories of NeuroCOVID vulnerability and their impact at population level. For this we leverage two leading national health registries and three clinical cohorts to characterize the phenotypic spectrum of NeuroCOVID, its risk factors and its socioeconomic burden at high definition. We pioneer innovative robotics to scale brain organoid modelling and combine it with single cell multiOMICs and AI analytics to dissect the principles of the individual host response and render experimentally actionable the authentic genetic backgrounds of differential SARS-CoV-2 sensitivity. Through a substantive engagement of patients’ collectives and health care stakeholders, upstream integration of innovative pipelines streamlines translation and operationalizes precision medicine for emerging medical needs.

Coordinatore

DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
Contribution nette de l'UE
€ 1 840 030,00
Indirizzo
VENUSBERG-CAMPUS 1/99
53127 Bonn
Germania

Mostra sulla mappa

Regione
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 1 840 030,00

Partecipanti (11)